Quoin Pharmaceuticals, Ltd.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-07 | -2.26 | -1.77 | +21.68% |
| 2026-03-26 | -4.02 | -1.74 | +56.72% |
| 2025-11-06 | -1.92 | -6.70 | -248.78% |
| 2025-08-07 | -6.83 | -6.28 | +8.05% |
| 2025-05-13 | -4.20 | -6.50 | -54.81% |
| 2025-03-13 | -15.05 | -9.73 | +35.33% |
| 2024-11-08 | -0.40 | -16.51 | -4026.50% |
| 2024-08-08 | -20.30 | -13.67 | +32.67% |
| 2024-05-09 | -14.35 | -38.62 | -169.12% |
| 2024-03-13 | -81.03 | -72.80 | +10.15% |
| 2023-11-09 | -95.32 | -68.25 | +28.40% |
| 2023-08-03 | -96.60 | -73.48 | +23.94% |
| 2023-05-09 | -96.60 | -144.10 | -49.17% |
| 2023-03-09 | -214.20 | -173.80 | +18.86% |
| 2022-11-10 | -495.60 | -395.26 | +20.25% |
| 2022-08-18 | -1158.15 | -1360.80 | -17.50% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| QNRX | -18.52% | -40.47% | -64.93% | -42.11% |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | -21.49% | -35.64% | -61.49% | -54.73% |